☆ 4.1 Article

Latest advances in immuno-oncology for endometrial cancer: single-agent and combination regimens

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program

T. Bosse et al.

Summary: The RAINBO program aims to investigate molecular class-directed adjuvant treatment strategies for endometrial cancer, with the goal of improving clinical outcomes and reducing toxicity. It consists of four international clinical trials and an overarching research program to advance knowledge of predictive and prognostic markers.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2023)

添加到收藏夹

Article Oncology

A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update

Vicky Makker et al.

Summary: Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. In this study, researchers reported the long-term follow-up efficacy and safety data of lenvatinib plus pembrolizumab in previously treated advanced endometrial carcinoma patients, which showed extended efficacy and tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Obstetrics & Gynecology

FIGO staging of endometrial cancer: 2023

Jonathan Berek et al.

Summary: Since the last update of the FIGO staging system in 2009, significant advancements have been made in understanding the pathology and molecular features of endometrial cancer. The new staging system aims to better define prognostic groups and create substages that guide appropriate treatment options. The proposed system incorporates data from molecular and histological classifications, providing a more comprehensive understanding of the complex nature of endometrial carcinoma and its biological behavior.

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2023)

添加到收藏夹

Article Oncology

Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775

Vicky Makker et al.

Summary: This article reports the final prespecified analysis of the Study 309/KEYNOTE-775, which is an open-label, randomized, phase III trial. The results show that lenvatinib plus pembrolizumab improves overall survival, progression-free survival, and objective response rate compared to chemotherapy in patients with advanced endometrial cancer. The combination therapy also demonstrates improved efficacy and manageable safety in various subgroups.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander et al.

Summary: This study collected data from 816 patients with endometrial cancer and found that adding pembrolizumab to standard chemotherapy significantly prolonged progression-free survival in advanced or recurrent endometrial cancer patients compared to chemotherapy alone.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M. R. Mirza et al.

Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001

Christian Marth et al.

Summary: The combination of pembrolizumab plus lenvatinib has shown promising efficacy in treating advanced endometrial cancer patients, especially those who have had limited previous treatment. Randomized controlled trials have demonstrated that this combination therapy has superior outcomes in terms of objective response rates, progression-free survival, and overall survival compared to chemotherapy.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2022)

添加到收藏夹

Article Oncology

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O'Malley et al.

Summary: Pembrolizumab demonstrated durable antitumor activity and encouraging survival outcomes in previously treated patients with MSI-H/dMMR endometrial cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin et al.

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Article Obstetrics & Gynecology

Executive Summary of the Uterine Cancer Evidence Review Conference

David Chelmow et al.

Summary: The Centers for Disease Control and Prevention recognized the need for educational materials on gynecologic cancers and convened a panel of experts to review relevant literature and guidelines. This article serves as an evidence summary and provides guidance for clinicians on uterine cancer.

OBSTETRICS AND GYNECOLOGY (2022)

添加到收藏夹

Article Oncology

Cancer treatment and survivorship statistics, 2022

Kimberly D. Miller et al.

Summary: The number of cancer survivors in the United States is increasing due to population growth, aging, and improved detection and treatment. The most prevalent cancers are prostate, skin melanoma, and colon and rectum for males, and breast, uterine corpus, and thyroid for females. Treatment disparities exist, with Black patients being less likely to be diagnosed with early-stage cancer and having lower surgical receipt rates.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.

Brian M. Slomovitz et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

Nicole Concin et al.

Summary: The European consensus conference on endometrial carcinoma in 2014 aimed to produce multi-disciplinary evidence-based guidelines. Since then, the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) have decided to update the guidelines and cover new topics to improve care for women with endometrial carcinoma globally.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

ENGOT-EN6/GOG-3031/NSGO-CTU-RUBY part 2: A phase III, randomized, double-blind, study of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo (PBO) plus carboplatin-paclitaxel followed by PBO in recurrent or advanced endometrial cancer (EC)

M. R. Mirza et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

Toon Van Gorp et al.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Microsatellite instability: a review of what the oncologist should know

Kai Li et al.

CANCER CELL INTERNATIONAL (2020)

添加到收藏夹

Review Obstetrics & Gynecology

Molecular characterization of endometrial cancer and therapeutic implications

Boris Winterhoff et al.

CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2020)

添加到收藏夹

Article Oncology

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer

Vicky Makker et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

DUO-E/GOG-3041/ENGOT-EN10: a randomized phase III trial of first-line carboplatin (carb) and paclitaxel (pac) in combination with durvalumab (durva), followed by maintenance durva with or without olaparib (ola), in patients (pts) with newly diagnosed (nd) advanced or recurrent endometrial cancer (EC).

Shannon Neville Westin et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

Raju K. Vaddepally et al.

CANCERS (2020)

添加到收藏夹

Review Biochemistry & Molecular Biology

Mismatch Repair Pathway, Genome Stability and Cancer

Nives Pecina-Slaus et al.

FRONTIERS IN MOLECULAR BIOSCIENCES (2020)

添加到收藏夹

Article Oncology

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer

Anne Sophie V. M. van den Heerik et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

添加到收藏夹

Article Oncology

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

A review of cancer immunotherapy: from the past, to the present, to the future

K. Esfahani et al.

CURRENT ONCOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway

Yu Kato et al.

PLOS ONE (2019)

添加到收藏夹

Review Oncology

Current recommendations and recent progress in endometrial cancer

Rebecca A. Brooks et al.

CA-A CANCER JOURNAL FOR CLINICIANS (2019)

添加到收藏夹

Article Oncology

Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: Multicenter, open-label phase 2 trial

Kenji Tamura et al.

CANCER SCIENCE (2019)

添加到收藏夹

Article Oncology

Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

Joyce F. Liu et al.

GYNECOLOGIC ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series

S. Kommoss et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer

L. Gandhi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

Nicholas McGranahan et al.

SCIENCE (2016)

添加到收藏夹

Article Medicine, General & Internal

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

D. T. Le et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Review Oncology

Milestones of Lynch syndrome: 1895-2015

Henry T. Lynch et al.

NATURE REVIEWS CANCER (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Integrated genomic characterization of endometrial carcinoma

Gad Getz et al.

NATURE (2013)

添加到收藏夹

Review Oncology

The blockade of immune checkpoints in cancer immunotherapy

Drew M. Pardoll

NATURE REVIEWS CANCER (2012)

添加到收藏夹

Article Obstetrics & Gynecology

Comparative Performance of the 2009 International Federation of Gynecology and Obstetrics' Staging System for Uterine Corpus Cancer

Sharyn N. Lewin et al.

OBSTETRICS AND GYNECOLOGY (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.